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Abstract: Toxoplasmosis may be transferred by organ
transplantation. The most common clinical presentation is with
multisystem disease, although isolated ocular toxoplasmosis has been
described. Many centers have suggested that universal use of co-
trimoxazole prophylaxis obviates the need for specific Toxoplasma
testing. We report a case of donor-acquired ocular toxoplasmosis after
liver transplantation despite co-trimoxazole prophylaxis. The diagnosis
was confirmed by Toxoplasma polymerase chain reaction assay in
conjunction with seroconversion. The fact that the infection was donor
acquired was confirmed by serological mismatch and the absence of
sporozoite-specific antigen antibody in the recipient.
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Ocular toxoplasmosis is a major cause of uveitis
worldwide and may be particularly aggressive in the
immunosuppressed (1). Transfer of the causative agent
Toxoplasma gondii through transplantation has been
reported for all solid organs, although infection most
commonly presents with multisystem disease (2).
Incidences vary between transplant programs, and it
has been suggested that universal prophylaxis with co-
trimoxazole (TMP/SMX) is sufficient to obviate the
need for Toxoplasma testing (3). Here, we report a case
of donor-acquired isolated ocular toxoplasmosis despite
TMP/SMX prophylaxis, occurring 7 months after liver
transplantation.
Case report
A previously healthy 32-year-old British female patient
presented with fulminant liver failure due to seroneg-
ative hepatitis. She received super-urgent orthotopic
liver transplantation from a brainstem dead UK donor.
The recipient was seronegative for cytomegalovirus
(CMV), but the donor was positive. The post-transplant
course was complicated by 2 episodes of acute rejection
requiring high-dose corticosteroids, in addition to
standard immunosuppression with tacrolimus and
mycophenolate. At discharge, liver biochemistry was
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normal. As per unit policy, she received 3 months of
TMP/SMX and valganciclovir prophylaxis to prevent
Pneumocystis jirovecii pneumonia and CMV infection,
respectively.
Seven months after transplantation, painless blurred
vision affecting the left eye developed over several
days. The patient had been well in the intervening
period, with no other symptoms, and she was afebrile.
External ocular examination was unremarkable. Fun-
doscopy of the left eye revealed 2 foci of chorioretinitis:
an active nasal lesion and a temporal lesion that had
largely progressed to chorioretinal atrophy. An overly-
ing vitreous hazing was consistent with mild vitritis
(Fig. 1).
As the differential diagnosis included Toxoplasma or
CMV chorioretinitis, empirical therapy with ganciclovir and
clindamycin was commenced initially. An aqueous humor
sample revealed the presence of leukocytes, but routine
microbiological cultures and polymerase chain reaction
(PCR) for CMV and varicella zoster virus were negative.
Toxoplasma gondii DNA was detected by real-time
PCR amplification of a region of the RE gene (GenBank
Accession no. AF146527). Serum Toxoplasma
immunoglobulin (Ig)M was positive and IgG negative;
IgG became weakly positive 20 days later. Retrospec-
tive testing of stored pre-transplant recipient serum
showed absence of anti-Toxoplasma IgG and IgM,
whereas donor serology was Toxoplasma IgG positive.
Ganciclovir was discontinued, the patient completed
a course of clindamycin, and her vision normalized over
several weeks. Subsequently, testing for a sporozoite-
specific antibody, according to the method described
by Hill et al. (4), was negative (anti-TgERP O.D. 0.198;
positive cutoff >0.4).
Long-term TMP/SMX secondary prophylaxis was
commenced to prevent future recurrences, although
was subsequently withdrawn because of myelosuppres-
sion. The patient went on to have a successful
pregnancy while taking only tacrolimus and pred-
nisolone immunosuppression.
On review of possible risk factors for acquiring
toxoplasmosis, it was established that the patient had
been given and followed routine advice to wash
vegetables and to cook meat thoroughly. She had
contact with her mother’s healthy adult cat, but did not
provide care for it.
Discussion
This is the first reported case, to our knowledge, of
Toxoplasma chorioretinitis occurring after liver trans-
plantation despite TMP/SMX prophylaxis. Donor–
recipient Toxoplasma serological mismatch (seroposi-
tive donor to seronegative recipients; D+R), the
onset of symptoms occurring 4 months after discon-
tinuing prophylaxis, the absence of sporozoite-specific
antibody, and the lack of other obvious routes of
acquisition suggest that our case could represent
donor-acquired infection. Of particular interest in
suggesting the route of acquisition is the negative
sporozoite-specific antibody. In contrast, in a large US
series of congenital toxoplasmosis, positive results of
this assay suggested that the majority of such cases
represent oocyst ingestion, even in the absence of risk
behaviors (5).
Toxoplasma donor–recipient mismatch was a
significant risk factor for post solid organ transplant
toxoplasmosis across multiple solid organ types in a
case–control series (6). The rate of infection appeared to
be highest with heart transplantation, and this has been
attributed to the Toxoplasma bradyzoite cysts’ predilec-
tion for muscle tissue including myocardium (7).
Furthermore, reports of separate recipients developing
toxoplasmosis from kidney grafts from the same donor
suggest that transferred infection can occur (6, 8).
The incidence of new Toxoplasma infection in the UK
population is 0.25–0.5% per year, while toxoplasmosis of
any presentation in donor–recipient mismatch has been
reported at up to 40% across all solid organs (6, 9).
Given that the cat in this case was adult and healthy,
that living with fewer than 3 kittens is not a significant
risk factor for acquisition of Toxoplasma, that other
family members remained well, and that serum
Fig. 1. Wide-field photograph of patient’s left fundus, with eyelash
artifacts inferiorly. Nasal region (left of the printed image) contains an
active focus of chorioretinitis; the temporal region contains a region
of chorioretinitis that has progressed to atrophy. Mild hazing caused
by vitritis.
806 Transplant Infectious Disease 2016: 18: 805–808
Webb et al: Ocular toxoplasmosis after liver transplant
sporozoite-specific antibody was negative, we believe
feline contact to be an unlikely route of infection in this
case (10).
A November 2015 Medline/PubMed search for
“toxoplasmosis” and “transplantation” returned 506
abstracts, with 3 previous cases of possible donor-
derived ocular toxoplasmosis following orthotopic liver
transplantation (11–14). None received prophylaxis
(Table 1). Our patient presented 7 months after trans-
plantation and 4 months after cessation of prophylaxis.
This is in contrast to a median of 31 days after
transplantation for a series of all presentations of
toxoplasmosis in liver transplant recipients (6) and
86.5 days among all solid organ transplants (12);
however, details of prophylaxis are incomplete in the
former study. The reported onset of isolated Toxo-
plasma chorioretinitis ranges from 21 days (11) to
9 months (6), and toxoplasmosis among all solid organ
transplants is reported to be delayed in its presentation
by prophylaxis (476.28  415.70 days with prophylaxis
vs. 48.81  28.93 without), with no patients presenting
while on prophylaxis (15). We hypothesize that our
case’s presentation may have been altered by prophy-
laxis and/or corticosteroids given for rejection.
In this case, chorioretinitis was multifocal and vitritis
was mild. These findings are consistent with those seen
in human immunodeficiency virus/acquired immunod-
eficiency syndrome (HIV/AIDS) ocular toxoplasmosis
patients (16). This presentation is in contrast to the
immunocompetent host, where chorioretinitis is usu-
ally unifocal, may be accompanied by scars from
previous resolved episodes, and may have severe
overlying vitritis.
Laboratory diagnosis of toxoplasmosis traditionally
relies on the presence of IgM antibodies or on IgG
seroconversion. However, in immunocompromised
patients, seroconversion may be delayed and even
absent. The specificity and sensitivity of PCR is,
therefore, particularly useful (3).
Primary prophylaxis for the prevention of toxoplas-
mosis is used by many heart transplant centers. Some
advocate indefinite prophylaxis in donor–recipient mis-
match. For other solid organ transplant programs,
especially in the presence of a low background rate of
Toxoplasma IgG seropositivity in the population, and
where TMP/SMX Pneumocystis jirovecii prophylaxis is
routine, donors and recipients are not routinely tested
for the presence of evidence of past Toxoplasma
infection (15).
Little experience has been published on the need for
secondary prophylaxis after completing a treatment
course for a confirmed Toxoplasma infection in the
context of immunosuppression outside the HIV/AIDSRe
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population (17). Further studies are warranted given
the side effect profile and costs associated with agents
such as TMP/SMX; regular monitoring by blood PCR
may be an alternative strategy.
In summary, we present a case of toxoplasmosis
chorioretinitis in a liver transplant recipient. This is the
first such case, to our knowledge, reported after
prophylaxis, and we believe that it is likely to represent
graft transmission. The onset months after transplan-
tation, the relative rarity of the condition, and its
atypical presentation may delay diagnosis in similar
cases. We note the utility of parallel donor–recipient
serology and of PCR analysis of aqueous fluid. Toxo-
plasma infection is still a potential risk for the liver
transplant population despite widespread use of TMP/
SMX prophylaxis.
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